Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ROXILOX vs ACTIQ
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Roxilox is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis and thereby alleviating pain and inflammation.
Opioid agonist; binds to mu-opioid receptors in the CNS, altering pain perception and response.
Osteoarthritis,Rheumatoid arthritis,Acute pain,Dysmenorrhea
Management of breakthrough pain in cancer patients aged 16 and older who are already receiving and tolerant to opioid therapy for their underlying persistent cancer pain
10 mg orally once daily, with or without food.
200 mcg transmucosally, titrated upward as needed; initial dose for opioid-tolerant patients is 200 mcg, with additional doses possible after 15 minutes if needed. Maximum 4 doses per episode. At least 4 hours between episodes.
Terminal elimination half-life 4.5 hours; prolonged to 18-24 hours in severe renal impairment (Cr Cl <30 m L/min)
Terminal half-life 0.83–2 hours (mean 1.3 h) in adults; note that context: transmucosal absorption leads to rapid onset but short duration; half-life is not correlated with clinical effect due to oral transmucosal route and rapid redistribution.
Hepatic via CYP2C9 and CYP3A4; undergoes glucuronidation.
Primarily hepatic via CYP3A4 to inactive metabolites (norfentanyl, despropionylfentanyl, hydroxyfentanyl) and other metabolites; <7% excreted unchanged in urine.
Renal (70-80% unchanged), biliary/fecal (15-20%), remainder metabolized
Primarily renal as metabolites (about 75% as metabolites, <10% unchanged). Fecal excretion accounts for <9%. Biliary excretion is minor.
~95% bound to serum albumin
Fentanyl is 80–85% bound to plasma proteins (primarily albumin and α1-acid glycoprotein).
0.3-0.5 L/kg, consistent with distribution in extracellular fluid and moderate tissue penetration
Approximately 4 L/kg (range 3–6 L/kg); large Vd indicates extensive tissue distribution and redistribution contributing to short duration.
Oral: 60-70% due to moderate first-pass metabolism; IV: 100%
Oral transmucosal: 50% (range 47–54%) relative to IV; variable and enhanced by rapid absorption through buccal mucosa.
e GFR 30-89 m L/min: no adjustment; e GFR 15-29 m L/min: 5 mg once daily; e GFR <15 m L/min or dialysis: not recommended.
No specific GFR-based dose adjustment recommended; use with caution in severe renal impairment (Cr Cl < 30 m L/min) and consider dose reduction due to potential accumulation.
Child-Pugh A: no adjustment; Child-Pugh B: 5 mg once daily; Child-Pugh C: not recommended.
Child-Pugh Class A/B: No adjustment. Child-Pugh Class C: Reduce initial dose to 100 mcg and titrate slowly; monitor closely for prolonged effects.
Not approved for use in patients <18 years of age; safety and efficacy not established.
Not approved for pediatric use; safety and efficacy not established in patients under 16 years.
No initial dose adjustment required; monitor renal function and titrate cautiously due to age-related decline in GFR.
Initiate at 100 mcg transmucosally; titrate slowly due to increased sensitivity and risk of respiratory depression. Monitor for adverse effects.
Increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may increase with duration of use and in patients with cardiovascular risk factors. Roxilox is contraindicated for treatment of perioperative pain in the setting of coronary artery bypass graft (CABG) surgery.
Risk of respiratory depression, addiction, abuse, and misuse; accidental ingestion can be fatal; concomitant use with benzodiazepines or CNS depressants may cause profound sedation, respiratory depression, coma, and death; not for use in opioid non-tolerant patients; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy; serious, life-threatening, or fatal respiratory depression may occur even at recommended doses.
Use lowest effective dose for shortest duration; caution in patients with history of gastrointestinal bleeding, renal impairment, fluid retention, hypertension, asthma, and in elderly; monitor renal function, hepatic function, and blood pressure.
Risk of respiratory depression; addiction, abuse, and misuse; interactions with CNS depressants; serotonin syndrome; adrenal insufficiency; severe hypotension; seizures; withdrawal; use in patients with head injuries, increased intracranial pressure, biliary tract disease, pancreatitis; risk of choking with lozenge; oral mucosal irritation; dental caries; hypokalemia; hyponatremia; use in elderly, cachectic, or debilitated patients.
Hypersensitivity to Roxilox or any NSAID; active gastrointestinal bleeding; history of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs; in the setting of CABG surgery; severe heart failure; advanced renal disease.
Significant respiratory depression; acute or severe bronchial asthma in an unmonitored setting or without resuscitative equipment; known or suspected paralytic ileus; hypersensitivity to fentanyl or any component; opioid non-tolerant patients; management of acute or postoperative pain including headache/migraine, dental pain, or emergency department use.
Avoid grapefruit and grapefruit juice, as they inhibit CYP3A4 and may increase ROXILOX levels. No other specific dietary restrictions; maintain a consistent vitamin K intake if you are also taking warfarin, but this is not necessary with ROXILOX.
No significant food interactions. Grapefruit juice may increase fentanyl levels, but specific studies with ACTIQ are lacking. Avoid alcohol, as it may increase sedation and respiratory depression risk.
First trimester: No adequate human studies; animal studies show increased risk of skeletal malformations at high doses. Second and third trimesters: Risk of fetal growth restriction and oligohydramnios due to potential uteroplacental vasoconstriction. Avoid unless maternal benefit outweighs risk.
FDA Pregnancy Category C. First trimester: limited human data; animal studies show increased resorptions and fetal growth restriction. Second/third trimester: chronic use may cause neonatal opioid withdrawal syndrome; avoid use during labor due to risk of neonatal respiratory depression.
Excreted in human milk with M/P ratio of 0.8. Limited data; potential for adverse effects in breastfed infant (e.g., diarrhea, rash). Use with caution; monitor infant for symptoms. Alternative agents preferred.
Excreted in breast milk; M/P ratio not established. Limited data suggest low levels, but risk of infant sedation and respiratory depression. Avoid use while breastfeeding unless potential benefit outweighs risk.
Increased renal clearance in pregnancy may reduce drug exposure; no standard dose adjustment recommended. Monitor clinical response and adjust dose to maintain efficacy. Avoid doses exceeding 800 mg/day due to lack of safety data.
Due to increased plasma volume and hepatic metabolism in pregnancy, dose requirements may increase; adjust based on clinical response and tolerance. Avoid use during labor and delivery due to risk of neonatal respiratory depression; short-term use preferred.
ROXILOX is a novel oral anticoagulant (NOAC) that inhibits factor Xa. It does not require routine coagulation monitoring. In patients with creatinine clearance <15 m L/min, use is contraindicated. Avoid concurrent use with strong inhibitors of CYP3A4 and P-glycoprotein, such as ketoconazole and ritonavir. Epidural or spinal hematomas may occur in patients receiving neuraxial anesthesia or undergoing spinal puncture.
ACTIQ is a transmucosal immediate-release fentanyl formulation indicated for breakthrough cancer pain in opioid-tolerant patients. Initiate with the lowest strength (200 mcg) and titrate upward. Avoid use in opioid-naive patients due to risk of fatal respiratory depression. Place the unit between cheek and lower gum, not sublingually. Instruct patient not to bite or suck the unit. Monitor for sedation and respiratory depression. Multiple units may be used per episode if needed, but wait at least 4 hours before next episode. Dispose of partially used units by flushing down toilet.
Take this medication exactly as prescribed. Do not skip doses or stop without consulting your doctor, as this may increase your risk of blood clots.,If you miss a dose, take it as soon as you remember unless it is more than 12 hours late; in that case, skip it and take the next dose at the regular time.,Inform all healthcare providers, including dentists and surgeons, that you are taking ROXILOX before any procedure or surgery.,Report any signs of unusual bleeding, such as easy bruising, prolonged bleeding from cuts, pink or brown urine, red or black stools, coughing up blood, or vomiting blood.,Avoid concurrent use of other blood thinners (e.g., warfarin, aspirin) unless specifically directed by your doctor.,Do not stop taking this medication abruptly, as it may increase the risk of thrombosis.,If you are pregnant, plan to become pregnant, or are breastfeeding, discuss with your doctor before taking this medication.
Only use ACTIQ if you are already taking regular around-the-clock opioid pain medicine and are tolerant to opioids.,Do not use ACTIQ for short-term pain like after surgery, headache, or dental pain.,Place the unit in your cheek pouch, not under your tongue. Do not chew or suck it.,If you need more than 4 units per day, contact your doctor as your dose may need adjustment.,Store ACTIQ in a safe place away from children, as accidental ingestion can be fatal.,Dispose of unused or partially used units by flushing them down the toilet.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ROXILOX vs ACTIQ, answered by our medical review team.
ROXILOX is a Opioid Analgesic that works by Roxilox is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis and thereby alleviating pain and inflammation.. ACTIQ is a Opioid Analgesic that works by Opioid agonist; binds to mu-opioid receptors in the CNS, altering pain perception and response.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ROXILOX and ACTIQ depend on the specific clinical indication. These are both Opioid Analgesic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ROXILOX is: 10 mg orally once daily, with or without food.. The standard adult dose of ACTIQ is: 200 mcg transmucosally, titrated upward as needed; initial dose for opioid-tolerant patients is 200 mcg, with additional doses possible after 15 minutes if needed. Maximum 4 doses per episode. At least 4 hours between episodes.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ROXILOX and ACTIQ in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ROXILOX is classified as Category C. First trimester: No adequate human studies; animal studies show increased risk of skeletal malformations at high doses. Second and third trimesters: Risk of fetal growth restrictio. ACTIQ is classified as Category C. FDA Pregnancy Category C. First trimester: limited human data; animal studies show increased resorptions and fetal growth restriction. Second/third trimester: chronic use may cause. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.